GeneDx Holdings Lowers FY2026 Sales Guidance from $540.000M-$555.000M to $475.000M-$490.000M vs $550.216M Est

Benzinga Newsdesk www.benzinga.com Negative 95.9%

Neg 95.9% Neu 0% Pos 0%

GeneDx Holdings (NASDAQ:WGS) lowers FY2026 sales outlook from $540.000 million-$555.000 million to $475.000 million-$490.000 million vs $550.216 million estimate.